Correction to: The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
After the publication of this work [1], an error was noticed in Fig. 2b, Fig. 3a and Fig. 5b. The Skp1 loading control was accidentally duplicated. We apologize for this error, which did not affect any of the interpretations or conclusions of the article.
Main Authors: | Ma’anit Shapira, Eli Kakiashvili, Tzur Rosenberg, Dan D. Hershko |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | Breast Cancer Research |
Online Access: | http://link.springer.com/article/10.1186/s13058-018-1000-4 |
Similar Items
-
The Prognostic Role and Expression of the Ubiquitin Ligase Subunits Skp2 and Cks1 in Hepatocellular Carcinoma
by: Chinh-wen Huang, et al.
Published: (2007) -
Targeting the mTOR-DEPTOR Pathway by CRL E3 Ubiquitin Ligases: Therapeutic Application
by: Yongchao Zhao, et al.
Published: (2012-05-01) -
Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
by: James T. Murray, et al.
Published: (2018-05-01) -
Inhibition of mammalian target of rapamycin (mTOR) in epidermis
by: Sully, Katherine L.
Published: (2012) -
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
by: Pei-Jie Shi, et al.
Published: (2016-02-01)